Vaxil Bio Licenses P-Esbp for Targeted Cancer Therapy from BGN Technologies, the Technology Transfer Company of Ben-Gurion University, Israel

NEXT STORY
Beroni Group Incorporates New PENAO Company with University of New South Wales to Develop the Next Generation Anti-Cancer Drug
PREV STORY
‘Absorbable’ Surgical Sutures to Witness Rapid Adoption, Key Market Players Focus on Competitive Pricing Strategies for Extended Outreach: Fact.MR
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AMAG Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Reaffirms 2019 Financial Guidance and Announces Consolidation of Women’s Health and Maternal Health Sales Forces ...

author_avatar
NASDAQ Market News

Bavarian Nordic to Host Capital Markets Day in New York City

COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will ...

author_avatar
NASDAQ Market News

Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study

MADISON, Wis., July 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage ...

author_avatar
NASDAQ Market News